|
Recent Developments |
|
22-MAY-17
Neuland Laboratories has entered into a Joint Development Agreement (JDA) with Phoenix Embassy Techno Zone (Developer) for development of the land owned by the company at Nanakramguda.
09-APR-14
Neuland Laboratories, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, announced that it has opened a new manufa... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015(12) | 31-Mar-2014 (12) | | Net sales | 4855.34 | 4478.91 | 4656.93 | | Other Income | 48.82 | 44.94 | -35.49 | | Total Income | 4904.16 | 4523.85 | 4621.44 | | Cost of goods sold | 4342.12 | 4027.86 | 3927.58 | | OPBDIT | 562.04 | 495.99 | 693.86 | | PAT | 264.16 | 157.81 | 266.68 | | Gross Block | - | - | - | | Equity capital | 89.54 | 89.54 | 77.26 | | EPS (Rs.) | - | - | 34.87 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | 2.54 - 10.62 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 11.5 | 11.0 | 15.0 | | Net margin (% of OI) | 5.4 | 3.5 | 5.8 |
|
|
Detailed Financials
|
|
|
|
|
